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Abstract: This is a review of randomized controlled trials using docosahexaenoic acid (DHA) in-
terventions in the first 1000 days of life with assessments of behavioral functioning in childhood.
Electronic databases were searched for trials with a DHA intervention (compared with a placebo
group that received no or less DHA) at any time to either women or infants during the first 1000 days,
with a subsequent assessment of child behavior. There were 25 trials involving 10,320 mother–child
pairs, and 71 assessments of behavior in 6867 of the children (66.5% of those originally enrolled).
From the 71 assessments administered, there were 401 comparisons between a DHA group and a
control group, with most reporting a null effect. There were no findings of a positive effect of DHA,
and 23 instances where the DHA group had worse scores compared with the control group. There was
limited evidence that DHA supplementation had any effect on behavioral development, although
two of the largest trials with behavioral measures detected adverse effects. Future trials, and future
follow-ups of existing trials, should make an effort to evaluate the effect of DHA intervention on
behavioral functioning.
Keywords: DHA; omega-3 fatty acids; supplementation; behavior; behavioral problems; prenatal;
postnatal; neonatal; infant
1. Introduction
Nutrition during the first 1000 days is considered to be the most influential (non-genetic)
determinant of development [1–6]. Docosahexaenoic acid (DHA, 22:6n−3) is one nutri-
ent that has been identified as crucial for neurodevelopment during this key phase [7].
DHA is accumulated in neural tissue across childhood, but is accreted most rapidly be-
tween the last trimester through to 24 months of age [8–11]. By the end of the first
1000 days, the brain has grown to 80% of its adult size [12] and although neurodevelop-
ment continues across childhood, the foundations for later development are laid during
this early period. Inadequate nutrition during the first 1000 days is linked with poorer
developmental outcomes for children, even when nutritional status is subsequently cor-
rected [4,13–18]. In the case of inadequate DHA and brain development, animal studies
have demonstrated that severe prenatal deprivation results in reduced neural tissue DHA
in the offspring [19–23]. Likewise, infants born preterm who are deprived of the placental
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supply of DHA during the fetal brain growth spurt subsequently have lower neural tissue
DHA levels than term-born infants [9]. Children born preterm also have an increased risk
of poor behavioral functioning and behavioral problems when compared with their term-
born counterparts [24–29]. Behavioral problems can adversely impact school performance,
peer relationships, mental health, and even employment and income in adulthood [30].
Management of behavioral problems typically involves multiple ongoing strategies target-
ing individual symptoms of a disorder involving the individual, their parents, and often
their school. Such strategies are time and resource intensive, and hence there are often
barriers to their access and implementation. It is important to evaluate potential pro-
tective factors to promote optimal behavioral functioning. Ensuring appropriate DHA
during early brain development may be one strategy to contribute to optimal behavioral
functioning [10].
1.1. Behavioral and Emotional Functioning
Behavioral and emotional functioning generally refers to an individual’s conduct and
includes self-regulation of reactions to emotions and situations or environments, for ex-
ample regulating frustration or concentrating on a task. An individual’s self-regulation
and reactivity are often considered aspects of temperament as well as behavior. Behavioral
functioning naturally improves with age across early childhood as an individual learns to
regulate emotions, understands how to play with other children and builds relationships,
and develops the ability to imagine the perspectives of others. Challenging behaviors
such as having a tantrum or opposing parental instructions are common in childhood
and are a part of normal development. When challenging behaviors are more frequent or
severe, they can impact a child’s functioning and be diagnosed as a behavioral problem.
The most commonly occurring behavioral problems to be diagnosed in childhood are
Attention-Deficit/Hyperactivity Disorder (ADHD; inattention, which may or may not
coincide with impulsive behaviors and hyperactivity), Autism Spectrum Disorders (ASD;
a continuum of neurodevelopmental disorders with deficits in social engagement and com-
munication as well as repetitive behaviors), Anxiety Disorders (overly fearful or worried),
Oppositional Defiant Disorder (disobedience and resistance to authority) and Conduct Dis-
order (anti-social behaviors that violate rules or the rights of others). Behavioral problems
are typically categorized into either internalizing (primarily affect the internal psychologi-
cal environment, for example anxiousness) or externalizing problems (primarily outwardly
expressed such as aggression).
1.2. The Link between DHA and Behavior
DHA is a structural component of the phospholipid bilayer of all cell membranes as it
has an integral role in membrane fluidity [31]. Although present throughout the body, DHA
is concentrated in the cells of the central nervous system, particularly the brain, where it is
a prominent fatty acid [32,33]. DHA is essential for the growth and development of the
CNS and brain [34–36]. DHA is known to be involved in neurogenesis, signal transduction
and neurotransmission [37] and can enhance synaptic functions [38]; protect neural cells
from apoptotic death [39], and oxidative stress [37]; induce synaptic growth cones during
neuronal development [40,41]; influence neuron size [42,43]; stimulate neurite outgrowth in
PC12 cells [44]; regulate nerve growth factor [45], membrane-bound enzymes [32], and ion
channels [46] as well as dopaminergic and serotinergic neurotransmission [47,48].
The development of behavioral functioning is complex and likely involves the inter-
play of social, psychological and biological factors. Nutrients, such as DHA, may be one
modifiable contributor to behavioral development. Observational studies have indicated
a role for DHA in the pathology of numerous mental health issues [49–53]. Case–control
studies have demonstrated higher DHA status in controls when compared with children
with ASD [54] and ADHD [55] and it has been hypothesized that the rise in reports of ASD
and ADHD may be in part due to the imbalance of omega-3 and omega-6 fatty acids in
current Western diets [10,52]. See Cardoso et al. for a more in-depth review of observa-
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tional associations between DHA and child behavior, as well as a summary of the possible
biological mechanisms that may explain the role of DHA in behavioral disorders [10].
Interventional studies have explored DHA supplementation in childhood to assist in the
treatment of behavioral disorders [10], with both benefits [56,57] and null [58,59] effects
reported. As yet, there is little evidence to support the use of DHA supplements in the
treatment of behavioral disorders such as ASD [58], learning disorders [59] and ADHD [57].
Whilst it is not uncommon for associations to be detected between behavioral prob-
lems and concurrent DHA levels or DHA intake, prospective longitudinal studies are
needed to determine whether DHA exposure during the critical period of brain devel-
opment can prevent or reduce the symptoms of behavioral functioning. Observational
studies of prenatal DHA intake or status have assessed a range of developmental outcomes,
but mainly focusing on cognitive abilities [16,17,60–64]. The largest and most robust ob-
servational study explored intake of fish and seafood (naturally rich sources of DHA) in
5499 pregnant women and found that low intake was associated with poorer behavior
in children at 8 years of age [16]. A smaller observational study has similarly reported
that increased prenatal dietary DHA intake is associated with reduced hyperactivity at
9 years [62]. Other observational studies of DHA status and the omega-3:omega-6 ratio
fatty acid in cord blood have reported associations with reduced parent-rated symptoms
of ADHD [65] as well as internalizing behavior problems [66] at 7 years of age. As many
factors that are associated with dietary DHA in early life are also associated with behav-
ioral outcomes (for example socioeconomic status), randomized controlled trials (RCTs)
are needed to establish a causal pathway between early DHA exposure and later child
behavioral development [67].
There have been many DHA interventions evaluated in the first 1000 days, but to
date all have been restricted to a specific window, such as during pregnancy [68,69],
with preterm-born neonates (<37 weeks’ completed gestation) [70], to breastfeeding women [71],
and during infancy and/or toddlerhood [72]. Trials that have explored the effect of early
DHA supplementation on subsequent brain development have been focused on cognitive
assessments. Although occasional benefits have been reported, results are predominantly
null and the consensus from reviews is that the evidence does not support the hypothesis
that early DHA supplementation improves brain development [68–74]. The focus on cogni-
tive outcomes as an indication on brain development is partly driven by the importance
given to cognitive functioning for educational, general health and work outcomes, as well
as economic benefits and societal contributions [75] and partly because the areas of the
brain undergoing rapid development during the first 1000 days are the regions considered
responsible for governing cognition. Hence nutritional deficiency during this time has been
shown to have irreversible effects on cognitive outcomes [4]. However, the neurological
areas of the brain responsible for behavior are similarly developing rapidly across the
first 1000 days. Yet behavioral functioning has only occasionally been included as an
exploratory outcome in some DHA intervention RCTs in early life.
There has been no consideration given to collating and considering the evidence
for DHA supplementation in early life to effect development of child behavior as a
whole [68–72,74,76], despite the substantial interest in the role of DHA for behavioral
problems [10,52,53,57–59,77]. Furthermore, whilst adequate DHA is likely to be important
throughout the whole of the first 1000 days, only two reviews to date have attempted to
synthesize the evidence from RCTs conducted across this period and behavior was not a
reported outcome of either review [76,78]. Given the biological plausibility for the role of
DHA in behavioral functioning as well as the increasing body of evidence supporting the
importance of this role, further research is warranted [10]. This review will be the first to
amalgamate the totality of the evidence examining the effect of early DHA supplementa-
tion on behavioral functioning in childhood. We review RCTs with a DHA intervention
during the first 1000 days that include a measure of any aspect of behavioral functioning,
or behavioral problems.
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2. Materials and Methods
Our review was undertaken according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines [79].
2.1. Search Strategy
The Cochrane Central Register of Controlled Trials (CENTRAL) Current Contents
Connect, PsychInfo, and PubMed were searched for eligible RCTs in humans that were
written in English. Search results were screened to assess eligibility through the titles
and abstracts. Additionally, given that behavior is rarely a primary or main outcome
of DHA intervention studies, we reviewed the full text of any DHA RCTs that reported
child developmental outcomes. Where only abstracts were accessible, such as from con-
ference proceedings, these were included. Reference lists of included articles returned
by the search were checked for other eligible articles as well as reference lists of other
reviews [52,68,69,71,72,76,78]. PubMed was set up to email new publications identified by
the search on a monthly basis with new articles added to the review up until acceptance of
the manuscript.
2.2. Inclusion and Exclusion Criteria
Studies were eligible for inclusion in our review if an RCT in humans that was
published in English, included supplementation with DHA (or long-chain polyunsaturated
fatty acids in conjunction with DHA), included a placebo group without (or with less) DHA
(or other fatty acids), and where the intervention occurred during any time within the first
1000 days to either a mother or infant (so long as target recipient of the intervention was
the offspring), and the study reported a measure of child behavioral functioning, including
temperament and emotional functioning.
2.3. Data Extraction and Synthesis
Study details (such as study characteristics, intervention details, results and possible
sources of bias) were extracted from eligible studies into a table by one author (JFG).
Included studies were categorized and synthesized according to the intervention period as
(1) maternal interventions during pregnancy, (2) interventions for neonates born preterm,
(3) postnatal interventions for breastfeeding mothers, and (4) postnatal interventions
directly to infants or toddlers. Where interventions spanned more than one of these
categories (for example throughout pregnancy and breastfeeding), the RCT was considered
according to the period when the intervention commenced.
Assessments of behavioral functioning can be based on caregiver report, on teacher
ratings, clinician administered or self-reported by the individual. Caregiver reports have
the benefit of providing information about behavior in the child’s home environment but
are a subjective measure. Teacher reports are ideal for gauging the severity of symptoms in
a classroom environment and have the advantage that a teacher is likely comparing the
individual’s behavior to their age-matched peers. Clinician reports are the least subjective
but are least likely to reflect everyday behavioral functioning in an everyday environment.
Behavior assessments can capture overall functioning, or a specific domain (such as only
externalizing or only internalizing) or can target the specific symptoms of a specific be-
havioral disorder such as ADHD. Many assessments are age-normed (often sex-specific,
indicating whether the behavioral functioning of an individual child is appropriate for a
typical child of the same age). Unusual (extreme) scores can indicate a possible behavioral
problem. However, clinical diagnosis involves a range of clinician-administered assess-
ments and interviews to determine whether an individual meets the criteria to be classified
according to the Diagnostic and Statistical Manual of Mental Disorders, now in its fifth
edition. Outcome assessments of included studies were categorized and discussed as
(a) Diagnosed behavioral problems (such as by a psychologist, psychiatrist or pediatri-
cian) or use of prescription medication for a behavioral problem,
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(b) Clinician-administered general behavior measures and/or behavioral sub-scores of
other measures,
(c) Teacher-rated behavior measures,
(d) Parent-rated behavior measures,
(e) Self-reported behavior measures, and
(f) Sensitivity and/or subgroup analyses.
3. Results
Our search identified a total of 25 RCTs as eligible for inclusion, with relevant trial
outcomes or details published between 1999 and 2020 across 36 publications [80–115].
We excluded two potentially eligible trials, one that intervened with eggs (which contain
DHA as well as other nutrients that contribute to neurodevelopment) vs. no control
eggs [116] and another that commenced the intervention for the majority of children after
the first 1000 days period (18–38 months, mean 27 months) [117].
3.1. Characteristics of Included Studies
The 25 RCTs (see Table 1) enrolled a total of 10,320 participants and were predominantly
conducted in high-income countries (the United States (USA), Australia, Norway, Denmark, the
United Kingdom (UK), Germany, and the Netherlands) whilst five were undertaken in low- or
middle-income countries (Iran, Mexico, Bangladesh, Malawi, and Ethiopia) [80,89,90,93,106,115].
3.2. Sample and DHA Supplementation Details
3.2.1. Maternal Interventions during Pregnancy
There were 10 RCTs investigating the effect of prenatal supplementation in 5913 preg-
nant women [80–94].
Pregnant women were asked to consume daily capsules. The doses of DHA prescribed
daily were 120 [93], 300 [92], 400 [89,90], 600 [82,83], 800 [86–88], 1000 [91], 1020 [94],
1200 [80] and 2200 [84,85] mg per day. In one trial, women were provided with cereal bars to
consume most days, with each cereal bar containing 240 mg/DHA [81]. Supplementation
typically started mid-pregnancy and ended at birth [80–90]. Where supplementation
continued after birth through infant formula and supplements for breastfeeding mothers,
the intervention stopped at 30 days [93], 3 months [92], and 4 months of age [94]. Two trials
excluded preterm-born infants from their follow-ups [84,85,92].
3.2.2. Interventions for Neonates Born Preterm
Six RCTs with 1667 preterm infants administered a DHA intervention through sachets,
oil or powders that could be added to milk, capsules for breastfeeding mothers, or fortified
preterm infant formula [95–101,103–105]. Two trials compared a low or standard dose
of DHA to a higher dose of DHA [98–100,103,104]. The majority of trials commenced
their intervention within a week of birth, with the exception of one trial that commenced
when the infants were 10–16 months of age [101]. Three RCTs ceased the intervention at
discharge from hospital [95,98–100,103,104]. In one trial, infants were aged 9 months of
age when the intervention ceased [96,97]; and in another trial, infants were 24 months of
age [105]. The trial that delayed the intervention only commenced once formula feeding
and breastfeeding had stopped [101]. The amount of DHA any individual infant received
varied both within and between groups as dose was dependent on the amount of milk the
infant was able to tolerate throughout the duration of the intervention.
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Third-world setting with endemic
poverty, illiteracy, poor hygiene,
overcrowding and poor housing
Duration: 25 week preg to birth
Form: 4 capsules daily
Trt: n-3 3000 mg/day, DHA 1200
mg/day
Ctrl: soy oil
Age: 10 mo, n = 249
Wolke
-scores: 5 No diff
Judge, 2006 [81] USA; hospital N enrolled: 48
Trt:27, ctrl:21
Duration: 24 week preg to birth
Form: cereal bar
Trt: n-3240 mg/bar, average DHA 240
mg/day
Ctrl: corn oil
Age: 6 mo, n = 38
ICQ No diff
-sub-scores: 4 No diff
Age 12 mo, n = 28
RITQ No diff
-sub-scores: 9 No diff
Dunstan, 2008 [84]; Meldrum,
2015 [85] Australia; antenatal clinic
N enrolled: 98
Trt:52, ctrl:46
All had allergic disease
Excluded: normal diet includes >2 fish
meals/week
Duration: 20 week preg to birth
Form: 4 capsules daily
Trt: n-3 3300 mg/day, DHA 2200
mg/day
Ctrl: olive oil
Age: 2.5 years, n = 71
GMDS No diff
CBCL No diff
-sub-scores: 2 No diff
Age: 12 years, n = 50
CBCL parent No diff
-sub-scores: 3 No diff
CBCL child No diff
-sub-scores: 3 No diff

























follow-up n = 726 (preterm and
randomly selected term)
Duration: 18–21 week preg to birth
Form: 3 capsules daily
Trt: 800 mg DHA/day
Ctrl: vegetable oil
Age: 18 mo, n = 726
Bayley-III S-E No diff
-subgroup: girls/boys No diff
Bayley-III A-B No diff
-subgroup: girls/boys Trt girlsworse












-subgroup: girls/boys No diff
Diagnoses No diff




Conners 3TM AI-P Trt worse
Diagnoses No diff





















Excluded: if taking n-3
Duration: 18–22 weeks preg to birth
Form: 2 capsules daily
Trt: 400 mg/day DHA
Ctrl: olive oil
Age: 5 years, n = 797
BASC-2 No diff
-scores: 4 No diff
-sub-scores: 19 No diff
-subgroup: girls/boys No diff
-subgroup: maternal
intelligence No diff
-subgroup: SES No diff
-subgroup: home
environment No diff
Carlson, 2013 [82]; Colombo,
2019 [83] USA; antenatal clinics
N enrolled: 350
Trt:178, ctrl:172
Singleton, healthy, normal BMI
Duration: mean 14.5 weeks preg to
birth
Form: 3 daily capsules
Trt: 600 mg/day DHA
Ctrl: soy and corn oil
Age: 18 mo, n = 186
Bayley-II BRS No diff
Age: 36 mo, n = 141
BASC-2
-scores: 4 No diff
Age: 48 mo, n = 140
BASC-2
-scores: 4 No diff
Age: 60 mo, n = 140
BASC-2
-sub-scores: 4 No diff
Age: 72 mo, n = 140
BASC-2
-sub-scores: 4 No diff






Trt: 1 g DHA/day
Ctrl: NR
Age: 14–20 years, n = 1051
ADHD cases from registry No diff




















Duration: 24–28 weeks preg to 3 mo
Form: capsules
Trt: 300 mg DHA + 67 mg EPA/day
Ctrl: sunflower oil
Age: 4 mo, n = 91
Bayley-III S-E No diff
-subgroup: girls/boys No diff
Bayley-III A-B No diff
-subgroup: girls/boys No diff
Age: 12 mo, n = 83
Bayley-III S-E No diff
-subgroup: girls/boys No diff
Bayley-III A-B No diff
-subgroup: girls/boys No diff
Ostradrahimi, 2017 [93] Iran; health care centres N enrolled: 150
Trt:75, ctrl: 75
Duration: 20 weeks preg to 30 days
Form: capsules
Trt: 120 mg DHA + 180 mg EPA/day
Ctrl: liquid paraffin
Age: 4 mo, n = 148
ASQ S-P No diff
Age: 6 mo, n = 146
ASQ S-P No diff
Brei, 2017 [94] Germany; NR
N enrolled: 208
Trt:104, ctrl:104
Duration: 15 weeks preg to 4 mo
Form: capsules (+ dietary counselling
to lower AA intake)
Trt: 1020 mg DHA + 180 mg EPA/day
Ctrl: general dietary information
Age: 4 years, n = 119
CDI No diff
Age: 5 years, n = 130
CDI No diff
Interventions for Preterm (Born <37 Weeks’ Gestation) Neonates
Fewtrell, 2002 [95] UK; neonatal units
N enrolled: 195
Trt:95, ctrl:100
<37 week, birthweight <1750 g, FF




Age: 9 mo, n = 158
KPSDSI
-score: 2 No diff
















Fewtrell, 2004 [96]; Isaacs,
2011 [97] UK; neonatal units
N enrolled: 238
Trt:122, ctrl:116
<35 week, birthweight ≤ 2000 g
FF




Age: 9 mo C,A n = 117
KPSDSI No diff
Age: 10years, n = 107
BADSC No diff








Duration: from enteral feeds to
discharge from hospital or infant
finished the 100 mL bottle of oil
Form: oil added to breastmilk
Trt: 32 mg DHA + 31 mg AA/100 mL
breastmilk
Ctrl: soy oil
Age: 6 mo CA, n = 105
ASQ S-P No diff
Age: 20 mo CA, n = 92
ASQ S-P No diff
Makrides, 2009 [98]; Smithers,
2010 [99]; Collins, 2015 [100] Australia; neonatal units
N enrolled: 657
Trt:322, ctrl:335
Singletons and multiples <33 week
Small subset for follow-up at 26 mo
FF and BF
Duration: <5 days of starting full
enteral feeds to term equivalent
Form: preterm infant formula, 6
capsules daily to breastfeeding
mothers
Trt: formula 1% DHA
Ctrl: formula 0.35% DHA
Age: 3–5 years CA, n = 125
SDQ No diff






Health care consultation Trt worse
Prescription medication No diff
Age: 7 years CA, n = 604
SDQ No diff






















< 1250 g/≥1250 g No diff
BRIEF No diff






< 1250 g/≥1250 g No diff
Conners 3TM AI-P No diff
-subgroup: girls/boys Trt girlsworse
-subgroup: birthweight
< 1250 g/≥ 1250 g No diff
Diagnoses No diff
Prescription medication No diff




Singletons and multiples <35 week, no
longer FF or BF
Duration: 10–16 mo CA for 6 mo
Form: dissoluble powder
Trt: 200 mg DHA + 200 mg AA/day
Ctrl: 400 mg corn oil/day
Age: 16–22 mo, n = 377
IBQ-R/ECBQ






-subgroup: girls/boys No diff
-subgroup: birthweight <1250
g/≥1250 g No diff
BITSEA
-scores: 14 No diff

































<31 week/with risk of
neurodevelopmental impairment (such
as brain injury)
Duration: from full milk feeds for 2
years
Form: sachet to mix with milk or food
Trt: DHA 1% fatty acids
Ctrl: no DHA
Age: 12 mo, n = 41
VABS-II No diff
Age: 24 mo, n = 41
VABS-II No diff
Postnatal Interventions for Breastfeeding Mothers
Cheatham, 2011 [107]







Habitual fish intake below Danish
median
Duration: <7days for 4 mo
Form: muesli bars, cookies and
capsules
Trt: 4.5 g fish oil, 1.5 g LCPUFA
Ctrl: olive oil
Ref: high habitual fish intake







Argaw, 2018 [106] Ethiopia; NR
N enrolled: 360
Trt1:90, Trt2:89, Trt3:90, ctrl:91
BF healthy singletons




Trt1:mother—215 mg DHA + 285 mg
EPA, child—169 mg DHA + 331 mg
EPA
Trt2:mother—215 mg DHA + 285 mg
EPA
Trt3: child—169 mg DHA + 331 mg
EPA
ctrl: mother—corn oil, child—corn +
soy oil
Age: baseline, 6–12 mo, n =
NR
Denver No diff
ASQ S-E No diff
Age: after 6 mo, 12–18 mo, n
= 326
Denver No diff
ASQ S-E No diff
Age: after 12 mo, 18–24 mo, n
= 313
Denver No diff
ASQ S-E No diff
















Postnatal Interventions Directly to Infants and Toddlers
Auestad, 2001 [108] USA; children’s hospital
N enrolled: 404
Trt1:82, Trt2:80, ctrl:77, BF:165
Healthy term born
FF





BF: Trt1 and Trt2 formula if stopped BF






Bayley-II BRS No diff






Bayley-II BRS No diff









Age: 9 mo, n = 241 + BF = NR
KPSDSI No diff
Birch, 2000 [109] USA; hospitals
N enrolled: 119
Trt1:26, Trt2:27, ctrl:26, BF:40
Healthy term born
FF






Age: 18 mo, n = 76
Bayley-II BRS No diff





Duration: 2 mo to 6 mo
Form: formula
Trt: 0.3% DHA + 0.45% AA
Ctrl: no DHA
BF: Trt formula if stopped BF
Age: 9 years, n = 341
CBCL-Parent No diff
CBCL-Teacher No diff
















Drover, 2011 [110] USA; hospitals
N enrolled: 159










Age: 18 mo, n = 92
Bayley-II BRS No diff




Duration: 6 mo to 18 mo
Form: micronutrient
complementary food
Trt1: 50 g micronutrient-fortified lipid
spread; DHA dose NR
Trt2: 25 g micronutrient-fortified lipid
spread, DHA dose NR
Ctrl: micronutrient-fortified
corn–soy flour
Age 18 mo, n = 163
GMDS No diff
Meldrum, 2012 [113];
Meldrum, 2020 [114] Australia; antenatal clinic
N enrolled: 420
Trt:218, ctrl:202
All mothers had allergic disease
FF and BF
Excluded preterm
Duration: birth to 6 mo
Form: oil capsules
Trt: 250–280 mg/day DHA
Ctrl: olive oil
Age:18 mo, n = 413
Bayley-III S-E No diff
-sub-score: 1 No diff
Bayley-III A-B No diff












-subgroup: girls/boys Trt boysworse
TRF No diff
GRS, n = 66 No diff
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3.2.3. Postnatal Interventions for Breastfeeding Mothers
There were 2 eligible RCTs among 535 breastfeeding women [106,107]. A trial in
Ethiopia (where dietary DHA intake is reported to be habitually low) randomized mother–
infant pairs when infants were aged 6 to 12 months [106]. Mothers received capsules
and infants received a corn–soy blend micronutrient complementary food supplement for
12-months [106]. Maternal capsules contained 215 mg DHA and the infant supplement
provided 285 mg DHA [106]. Mother–infant pairs were randomized to 1 of 4 groups;
(1) mothers’ capsules contained DHA but infant supplements did not, (2) mothers’ capsules
and infant supplements both contained DHA, (3) infant supplements contained DHA but
mothers’ capsules did not, and (4) neither capsules not the infant supplement contained
DHA [106]. The other trial randomized infants within a week of birth and enrolled a refer-
ence group of mothers with habitually high dietary fish consumption [107]. Mothers were
offered capsules as well as fortified muesli bars and cookies to provide 1.5 g LCPUFA [107].
3.2.4. Postnatal Interventions Directly to Infants or Toddlers
Seven RCTs randomized 2205 infants and toddlers [108–115], the majority of which
were exclusively term-born infants [108–113]. One trial included both formula-fed and
breast-fed infants [113]. Five RCTs compared fortified infant formulas [108–112], one trial
provided micronutrient complimentary food [115], and oil capsules that could be added
to milk were provided in another [113]. Administered doses of DHA ranged from 0.12 to
0.96% of total fatty acids present in formula [108–112], or 250 to 280 mg DHA per day [113].
Supplementation went from 6 to 18 months of age in one trial [115], but most started within
a week of birth in most trials and lasted 4–12 months [108–113].
3.3. Assessments of Behavioral Functioning and Behavior Problems
Behavioral functioning was assessed at a total of 43 different times among the 25 RCTs
between 4 months and 20 years, with a total of 71 assessments and 401 group comparisons.
(a) Diagnosed behavioral problems (such as by a psychologist, psychiatrist or pediatri-
cian) or use of prescription medication for a behavioral problem
Three trials explored differences in diagnosed behavioral problems or use of pre-
scription medication for behavioral problems [87,88,91,100]. One study accessed national
medical records to ascertain prescriptions of medications for treating behavioral problems
and another accessed ADHD cases from a registry [91]. Parents reported diagnoses of
behavioral problems in two trials [87,88,100]; and in one of these trials, parents additionally
reported whether the child was taking any prescription medications for problem behavior
in one study [99,100]. In this same study, parents were asked whether they had consulted a
health care professional due to concerns for their child’s behavior [99].
(b) Clinician-administered general behavior measures and/or behavioral sub-scores of
other measures
There were only two studies that included a clinician-administered measure of be-
havior [80,97]. A modified Wolke five-scale measure was used to assess behavior at
10 months in Bangladesh [80]. The Wolke scale has no overall score but five scales for
activity, emotional tone, responsiveness to examiner, cooperation, and vocalization. In a
preterm infant trial, the Behavioral Assessment of the Dysexecutive Syndrome for Children
(BADSC) was administered when children reached 10 years of age [97].
A further nine studies involved a clinician-administered measure of another develop-
mental domain that included a behavioral subscale or score [83,84,95,96,108–110,112,115].
The Bayley Scales of Infant Development (Bayley) is considered by many internationally to
be the gold standard for assessing the development of infants and young children (up to
~3.5 years of age). There are multiple editions. The first and second editions includes a
Behavioral Rating Scale (BRS) that assesses the child’s behavior in relation to complying
with the instructions of the Bayley mental and motor assessments and was reported in
four trials [83,108–110]. In one of these trials, the BRS scores were age standardized and
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classified as questionable if scores fell below the 25th centile, and classified as non-optimal
if below the 10th centile [108]. The Griffiths Mental Development Scale (GMDS) is another
global developmental test from birth to 8 years that includes a Personal–Social scale and
was used in one trial at 2.5 years of age [84] and at 18 months of age in another trial [115].
The Knobloch, Passamanick and Sherrard’s Developmental Screening Inventory (KPSDSI)
is a general developmental screening test that includes subscales measuring Adaptive,
and Personal–Social behaviors. The KPSDSI was used in 2 preterm infant trials at 9 months
of age [95,96] and in an infant trial at 9 months of age [112].
(c) Teacher-rated behavior measures
There was only one included trial that involved a teacher-rated measure of behavior.
The Achenbach Child Behavior Checklist (CBCL) has eight empirically based syndrome
scales (Aggressive Behavior, Anxious/Depressed, Attention Problems, Rule-Breaking Be-
havior, Somatic Complaints, Social Problems, Thought Problems, and Withdrawn/Depressed)
and six DSM-oriented scales (Affective Problems, Anxiety Problems, Somantic Problems,
ADHD Problems, Oppositional Defiant Problems and Conduct Problems). The teacher-
rated, Dutch version of the CBCL was completed by teachers in one RCT in infants [111].
In an Australian trial, the Teacher Report Form (TRF) and the Gifted Rating Scale (GRS)
were administered to school teachers when children were 6 years of age [114].
(d) Parent-rated behavior measures
There were eight studies that included a parent-rated measure of general behav-
ior [84–88,90,92,100,102,111,113,114], an additional trial that included a parent-rated mea-
sure of development with a behavior score [93], and two trials that included parent-rated
measures of temperament [81,99].
The Bayley-III includes optional age-standardized parent-rated Social–Emotional [S-E]
and Adaptive-Behavior [A-B] scales, that were reported in two studies [86,92]. The Bayley-
III S-E measures self-regulation, impactful use of emotions and engaging with others,
and the A-B scale measures skills including self-care and self-direction, communication and
social domains. The Strengths and Difficulties Questionnaire (SDQ) is a brief screen of gen-
eral behavioral symptoms. The SDQ is summarized in an overall Total Difficulties score and
includes subscales for emotional symptoms, hyperactivity, conduct problems, peer prob-
lems, and prosocial behavior. There is an additional Impact scale as an optional indication
of whether or not the parent-perceived symptoms have a negative impact on the child’s
quality of life. Overall scores range from 0 to 40 points, with higher scores indicating more
problematic behavior (for all scores except the prosocial subscale). The SDQ was reported
at 7 years of age in 3 studies [88,100,107] and at 3–5 years in two of these RCTs [87,99].
The Behavior Rating Inventory of Executive Functioning (BRIEF) measures behavioral
manifestations of executive functions in the home environment. The BRIEF questionnaire
has a version for children aged 5 to 18 years that has an overall Global Executive Compos-
ite score, two index scores for Behavioral Regulation Index, and Metacognition Index as
well as subscale scores; Inhibit Scale, Shift Scale, Emotional Control Scale, Initiate Scale,
Working Memory Scale, Plan/Organize Scale, Organization of Materials Scale, and Monitor
Scale. The BRIEF was reported in two trials [88,100]. The BRIEF also has a version for
children aged 2 to 6 years, the BRIEF-Preschool (BRIEF-P) that was used in 1 trial [87].
The BRIEF-P likewise includes an overall Global Executive Composite score, three index
scores (Inhibitory Self-Control Index, Flexibility Index, and Emergent Meta-Cognition In-
dex) and subscales Inhibition Scale, Shift Scale, Emotional Control Scale, Working Memory
Scale, and Plan/Organize Scale. The BRIEF and BREIF-P scores are all scaled to a mean of
50 and SD 10, where a score greater than 64 is clinically indicative of dysfunction. The Con-
ners 3rd Edition ADHD/DSM-IV Index-Parent (Conners 3TM AI-P) measures Diagnostic
and Statistical Manual of Mental Disorders vIV—defined symptoms of ADHD. Scores are
age standardized to a mean of 50, SD 10, where a normal score is less than 60, and a score
above 60 indicates more concerns than typical for a child of that age. The Conners was used
in two trials [88,100]. The Brief Infant Toddler Social and Emotional Assessment (BITSEA)
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assesses socioemotional and behavioral problems in toddlerhood and was completed by
parents in one of the preterm trials [102]. The BITSEA is comprised of seven scales (Compe-
tence, Problem, Externalizing, Internalizing, Dysregulation, Red Flag, ASD) which authors
compared between groups as mean scores as well as dichotomized according to cut-off
scores indicating a possible behavioral problem [102]. This same trial also asked parents to
complete the Pervasive Developmental Disorders Screening Test-II (PDDST) to screen for
ASD in children with developmental concerns and again compared both the mean score and
proportion scoring over the cut off [102]. The Vineland Adaptive Behavior Scales (VABS) is
a parent-completed questionnaire that measures adaptive behavior and was administered
in one trial of preterm infants [105]. The CBCL includes a parent-rated version in addition
to the teacher-version and was used in three trials [84,85,111,113,114]. One trial that used
the parent-rated CBCL-derived seven scales (Emotionally Reactive, Anxious/Depressed,
Somatic Complaints, Withdrawn, Sleep Problems, Attention Problems, and Aggressive
Behavior) as well as the six DSM-oriented scales [113], whereas others reported just the
overall score and subscales for internalizing, externalizing, and (for older children) com-
petence [84,85]. The Behavioral Assessment System for Children (BASC)-2 has a Parent
Rating Scale to capture adaptive and maladaptive behaviors in the home and community
environment that was administered in two trials [83,90]. There is no overall score for the
measure but scales for Externalizing Problems, Internalizing Problems, Adaptive Skills
and Behavioral Symptoms [83,90]. In one of the trials, the Spanish version of the BASC-2
was adapted and administered through trained psychologists interviewing parents [90].
Infant Behavior Questionnaire (IBQ) is a parent-completed questionnaire for infants with a
complimentary version for older children, the Early Childhood Behavior Questionnaire
(ECBQ). There is no overall score, but each has several behavioral scales; the IBQ includes
activity level, distress to normal stimuli, distress to limitations, soothability, smiling and
laugher, duration of orienting. The ECBQ scales measure effortful control, and activity
level. Both the IBQ and ECBQ were used in 1 preterm infant trial when children were
16–22 months of age [101] and the IBQ was used at 6 and 12 months of age in one trial
in infants [108]. The Autism Spectrum Quotient: Children’s Version (AQ-Child) was
administered to parents of 6-year-old children in one trial [114].
The Denver Developmental Screening Test (Denver) is a global infant and early
childhood assessment that involves a combination of clinician-administered as well as
parent-reported components. One postnatal trial adapted the Denver-II for use in Ethiopia
and compared group scores on the Personal–Social subscale at enrollment into the trial,
after 6 months on the intervention and again 12 months after enrollment [106]. The Ages
and Stages Questionnaire (ASQ) is a parent-reported measure of global child development.
The ASQ includes subscales to capture aspects of behavior, dependent on the child’s age.
The ASQ was used in three trials, where the subscales reported were the Social–Emotional
[S-E] subscale [106] or Personal–Social [S-P] subscale [93,103,104]. The Child Development
Inventory (CDI) was another global measure that include a subscale for Social behavior.
The CDI was adapted in Germany and used in one prenatal trial at 4 and 5 years of age [94].
Temperament was assessed via parent-ratings in two trials [81,99]. In one trial of
preterm infants, parents completed the Short Temperament Scale for Children (STSC)
when children were 3–5 years of age [99]. The STSC provides an overall score as well as
subscales for approach, inflexibility, persistence, and rhythmicity. In one trial the Infant
Temperament Questionnaire (ICQ) was completed by parents at 6 months to gain an
overall score as well as subscales for fussy-difficult, unadaptable, dull, and unpredictable
behaviors [81]. In this same trial, infants were followed up again at 12 months with the
Revised Infant Temperament Questionnaire (RITQ) with another overall temperament
score and, subscales for activity, rhythmicity, approachability, adaptability, intensity, mood,
persistence, distractibility, and threshold [81].
(e) Self-reported behavior measures
There was only one self-reported assessment of behavior that was completed by
the child themselves. The CBCL, which also includes a teacher-rated and a parent-rated
Nutrients 2021, 13, 415 18 of 30
version, includes a self-reported version that was used in one study when children were
12 years of age [85].
(f) Sensitivity and/or subgroup analyses
Subgroups or sensitivity analyses, where reported, were explored for birthweight [100,101],
household income or SES [90,101], maternal intelligence [90], home environment [90],
and sex [86,87,90,92,97,100,101,107,114].
3.4. Effect of DHA Intervention of Behavioral Functioning
3.4.1. Maternal Interventions during Pregnancy
Of the 5913 pregnant women enrolled and randomized between 10 RCTs, there were
behavioral assessments of 3476 (58.8%) children [80–94]. Assessments were conducted
at 21 different ages between 4 months and 20 years of age. There were 28 measures of
behavior, with a total of 220 comparisons between groups, including tests within subgroups
and for interaction effects.
(a) Diagnosed behavioral problems (such as by a psychologist, psychiatrist or pediatri-
cian) or use of prescription medication for a behavioral problem
Two prenatal trials explored the effect of a DHA intervention on clinically diagnosed
behavioral problems [87,88,91]. A trial that accessed a registry for ADHD found no differ-
ences between their groups when the children were 14–20 years of age [91]. In one trial
that collected parent-reported medically diagnosed behavioral problems, there were no
differences in the proportion of ASD or ADHD at 4 years [87] or of any neurodevelopmental
disorders at 7 years [88].
(b) Clinician-administered general behavior measures and/or behavioral sub-scores of
other measures
There was only one prenatal study that included a clinician-administered measure
of behavior [80] and two studies with clinician-administered developmental measures
that included a behavioral subscale [83,84]. There were no group differences detected on
the clinician-administered adaptation of the Wolke scale in 10-month-old children [80].
The BRS of the Bayley-II was reported by one prenatal study at 18 months and no effect
of the DHA intervention was detected [83]. One trial included an objective measure of
behavioral development as subscale of a global developmental assessment at 2.5 years,
and detected no differences between the groups [84].
(c) Teacher-rated behavior measures
There were no reports of a teacher-rated measure of behavior.
(d) Parent-rated behavior measures
There were eight trials that involved a parent-rated measure of behavior [81,83,84,86–88,90,92–94]
and many of these studies administered parent-rated measures at more than one time
point [81,83,84,86–88,92,93].
One trial that reported using the Bayley-III to measure behavior at 4 months and at
12 months of age detected no group differences at either time point on either the S-E or
A-B scale [92]. Another trial involved multiple measures of parent-rated behavior from
infancy to school age [86–88]. At 18 months there was no effect of the DHA intervention on
the Bayley-III S-E or A-B [86]. Nor was there a difference in the overall BRIEF-P score at
4 years, although overall scores of the SDQ were slightly poorer in the DHA group [86].
All subscales for the BRIEF-P (three indices and five scales) and SDQ (six subscales) were
slightly poorer in the DHA group, although only the SDQ Hyperactivity scale, and the
BRIEF-P Emergent Meta-Cognition Index and Plan/Organize Scale reached a statistically
significant difference [86]. When the SDQ and BRIEF were completed at 7 years in this
same sample, overall scores were worse in the DHA group, as was the Conners 3TM AI-P
and the 2 Index scores reported for the BRIEF [88]. Subscale scores were not reported
for the SDQ or BRIEF in the 7 year follow-up [88]. Where scores differed between the
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groups in each of the comparisons, the magnitude was small (0.29 to 3.61 points) [87,88].
One prenatal trial administered the parent-rated CBCL with the overall score as well as
subscales for internalizing and externalizing behavior at 2.5 years and again at 12 years of
age [84,85]. At 2.5 years, authors additionally compared cut offs for scores indicative of a
clinical problem [84] and at 12 years there was an additional Competence sub-score [85].
The authors detected no group differences in any of these comparisons [84,85]. The BASC-
2 was administered at 26, 48, 60 and 72 months in one trial, with no group differences
detected at any age [83]. The BASC-2 was administered at 5 years in one of the largest
prenatal trials [90]. No group differences were reported for the scales for Externalizing
Problems, Internalizing Problems, Adaptive Skills or Behavioral Symptoms [90].
The global ASQ screen was completed by parents at 4 and 6 months in one trial, and no
effect of the DHA intervention was detected on the S-P subscale [93]. The CDI likewise
revealed no group differences when the social subscale was compared at 4 and 5 years of
age [94].
In the one trial that measured temperament with two measures, the ICQ at 6 months
and the RITQ at 12 months, no differences were reported on overall or any subscale
scores [81].
(e) Self-reported behavior measures
In the only trial that included a child self-report measure, administered at 12 years,
there were no effects of the intervention detected on the overall CBCL score, nor the
internalizing, externalizing or competency sub-scores, although the sample was small with
only 50 children included [85].
(f) Sensitivity and/or subgroup analyses
Of the 10 prenatal RCTs, 3 reported conducting any subgroup analyses [86–88,90,92],
for sex [86–88,90,92], maternal intelligence [90] and stimulation in the home environment as
well as socioeconomic status [90]. There were no interactions with sex detected at a 5-year
follow-up [90]. Subgroup analyses for sex on the parent-rated Bayley-III Social–Emotional
and adaptive behavior scores at 4 and 12 months did not reveal any sex by treatment
interactions [92]. One large trial showed that although there were no overall differences
in parent-rated behavior at 18 months [86], there was evidence that DHA group girls had
a lower (poorer) adaptive behavior scores [86]. The 4-year follow-up of these children
revealed no sex by treatment interaction [87] and the subgroup analyses were not reported
for the 7-year behavioral assessments [88]. Only one trial explored an interaction effect for
quality of stimulation in the home environment during childhood or socioeconomic status,
with no null effects found [90]. Nor was there any interaction between DHA intervention
and maternal intelligence [90].
3.4.2. Interventions for Neonates Born Preterm
Of the 1667 preterm infants enrolled and randomized, there were behavioral as-
sessments of 1402 (84.1%) children [95–105]. Assessments were conducted at 10 dif-
ferent ages from 6 months and 10 years of age. There were 19 measures of behavior,
with a total of 116 comparisons between groups, including tests within subgroups and for
interaction effects.
(a) Diagnosed behavioral problems (such as by a psychologist, psychiatrist or pediatri-
cian) or use of prescription medication for a behavioral problem
Although infants born preterm have an increased risk of developing behavioral
problems compared with infants born at term, diagnosed problems or use of medications
was only collected in one large trial [99,100]. More parents from the high-DHA group had
consulted a health care professional due to concerns for their child’s behavior, although no
children were taking any prescription medications for problem behavior at the time of the
follow-up (3–5 years of age) [99]. At 7 years of age in this cohort, there were no differences
in diagnoses of ADHD, ASD, and no differences in the use of ADHD medications [100].
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(b) Clinician-administered general behavior measures and/or behavioral sub-scores of
other measures
There were two trials with an assessment of behavior performed by a clinician [95–97].
One trial administered the BADSC at 10 years and found no difference in performance
between the groups [97]. Two trials both used the KPSDSI screening test at 9 months of age
which includes two subscales for Adaptive behavior and Personal–Social behaviors [95,96].
Neither test detected a difference [95,96].
(c) Teacher-rated behavior measures
None of the trials included a teacher-rated measure of behavioral functioning.
(d) Parent-rated behavior measures
Parent-rated measures of behavior were included in three of the six trials in preterm
samples [99–102,105], and one included global measures with a parent-rated behavioral
subscale [103,104]. One follow-up of a small subset from the larger trial included a parent-
rated assessment of temperament [99]. One trial used the VABS-II to assess adaptive
behavior at 12 and 24 months, and found no effect of the DHA intervention [105]. In one
large trial, no group differences were detected on mean overall or subscale scores of the
SDQ in a subset of the sample at 3–5 years of age [99]. When scores on the SDQ were
categorized as normal or abnormal, there were no group differences [99]. When the SDQ
was administered again in the larger sample at 7 years, there were no group differences
on overall or subscale scores [100]. Nor was there an effect on the BRIEF or Conners
3TM AI-P [100]. In a trial that supplemented preterm infants after weaning, parent-rated
behavior on the IBQ-R/ECBQ at 16–22 months detected no group differences in effortful
control or activity level [101]. Parents in this same trial also completed the BITSEA and
the PDDST-II at the same time, and no differences in any of the mean group scores were
detected [102]. When dichotomized by cut-off scores for clinical concern, there was no
effect on found on the seven BITSEA scales, but treatment group children were slightly less
likely to have scored in the clinically concerning range on the PDDST-II than the control
group children [102].
The ASQ (a measure of general development) was completed by parents at 6 months
and again at 20 months and the ASQ S-P subscale was compared between groups, with no
differences detected [103,104].
In the 1 trial that included a measure of temperament, there was 1 report of a negative
effect on 1 of 4 subscales of the STSC, and no effect on the overall score of the STSC in
one trial at 3–5 years of age [99]. The Persistence subscale at 3–5 years of age was slightly
poorer in the DHA group [99]. When STSC scores were categorized as normal or abnormal
there were no group differences [99].
(e) Self-reported behavior measures
There were no trials that included a self-reported measure of behavioral functioning.
(f) Sensitivity and/or subgroup analyses
Of the six preterm infant RCTs, half reported conducting a subgroup analysis [97,100–102].
Subgroup analyses were conducted for sex [97,100,102], birthweight [100,101], and house-
hold income [101]. One of the earlier RCTs found no sex by treatment interaction on
behavior at 10 years [97]. A recent trial identified no sex by treatment interaction at
16–22 months of age for the majority of outcomes measured, and one instance where a ben-
efit of the intervention was seen in symptoms of ASD among girls only, and one instance
where there was a benefit of the intervention on symptoms of ASD in boys only [101,102].
In a larger trial including both breastfed and formula-fed preterm infants, subgroup anal-
yses revealed a sex by treatment interaction on behavior at 7 years of age [100]. On the
Conners 3TM AI-P and the BRIEF, girls in the DHA group had consistently slightly poorer
scores for all outcomes, and the difference reached statistical significance on the overall
score as well as the Behavioral Regulation Index, Inhibit Scale, and Monitor Scale [100].
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Of the seven outcomes for the SDQ, girls similarly had consistently worse scores but only
the conduct problems subscale reached statistical significance [100]. Birthweight <1250 g or
>1250 g did not appear to interact with DHA in this same trial for any of these behavioral
outcomes [100]. Nor was there an interaction between birthweight and DHA treatment in
a smaller trial [101]. This trial also explored household income and found an interaction
effect with DHA supplementation where effortful control was slightly poorer in the DHA
group as household income increased [101].
3.4.3. Postnatal Interventions for Breastfeeding Mothers
Of the 535 breastfeeding women enrolled and randomized, there were behavioral
assessments of 424 (79.3%) children [106,107]. Assessments were conducted at 4 different
ages between 6 months and 7 years of age. There were 7 measures of behavior, with a total
of 18 comparisons between groups.
(a) Diagnosed behavioral problems (such as by a psychologist, psychiatrist or pediatri-
cian) or use of prescription medication for a behavioral problem
There were no explorations of diagnosed behavioral problems in either maternal
postnatal intervention trial.
(b) Clinician-administered general behavior measures and/or behavioral sub-scores of
other measures
Neither postnatal trial employed a clinician-administered measure of behavior.
(c) Teacher-rated behavior measures
None of the maternal postnatal intervention trials used a teacher-rated measure
of behavior.
(d) Parent-rated behavior measures
Both postnatal trials involved parent-rated measures [107]. In one trial, the SDQ was
used at 7 years and revealed no differences on Total Difficulties Score or the 5 subscale
scores [107]. The trial in Ethiopia detected no differences on the Denver-II subscale for
Personal–Social or ASQ S-E subscale [106].
(e) Self-reported behavior measures
Neither trial included a self-reported measure of behavior.
(f) Sensitivity and/or subgroup analyses
One postnatal trial tested for a sex by treatment interaction effect at 7 years of age [107].
Whilst the majority of SDQ scores revealed no group differences or interactions, the Proso-
cial Behavior Scale revealed an interaction in which treatment group boys had poorer
scores than control group boys [107]. Scores did not differ between treatment group and
control group girls [107].
3.4.4. Postnatal Interventions Directly to Infants or Toddlers
Of the 2205 infants enrolled and randomized into a RCT of infants or toddlers,
there were behavioral assessments of 1565 (71.0%) children [108–115]. Only one trial
included infants that were breastfed [113] and the majority included only term-born in-
fants [108–113]. Assessments were conducted at 9 different ages between 6 months and
6 years of age. There were 17 measures of behavior, with a total of 47 comparisons between
groups, including tests within subgroups and for interaction effects.
(a) Diagnosed behavioral problems (such as by a psychologist, psychiatrist or pediatri-
cian) or use of prescription medication for a behavioral problem
None of the RCTs supplementing infants or toddlers with DHA explored whether
there was an effect on diagnosed behavioral problems or receipt of medications used to
treat behavioral problem.
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(b) Clinician-administered general behavior measures and/or behavioral sub-scores of
other measures
There were three trials in infants that included a clinician-administered measure of
behavior [108–110] and one clinician-administered developmental measure that included
a behavioral subscale. The BRS score of the Bayley-II was compared between groups at
6 months of age and again at 12 months of age in one trial [108] and at 18 months in two
other trials [109,110]. No group differences were detected at any age in any trial [108–110].
The KPSDSI at 9 months revealed no effect of DHA intervention [112] and nor did the
GMDS at 18 months of age [115].
(c) Teacher-rated behavior measures
There were two trials that included a teacher-rated measure of behavior [111,114].
One trial provided teachers with the CBCL when the children were 9 years old [111].
No differences were detected between the groups [111]. An alternate trial asked teachers to
complete the TRF and GRS at 6 years, and likewise found no effect of DHA supplementa-
tion [114].
(d) Parent-rated behavior measures
There were three trials in infants that included one or more parent-rated measures of
behavior [108,111,113,114]. The IBQ at 6 and at 12 months of age revealed no effect of DHA
intervention on 5 of 6 subscale scores at both ages [108]. The smiling and laughter score was
slightly but statistically significantly poorer for the DHA group when compared with the
control group [108]. The Bayley-III S-E and A-B subscales were administered in 1 trial when
children were 18 months of age and no group differences were detected [113]. The CBCL
provided to parents when their children were 9 years of age in one trial [111], and at
18 months [113], and 6 years of age in another trial [114]. Comparisons revealed no effect of
DHA intervention on the overall CBCL scores [111,113,114]. When 13 CBCL subscales were
compared at 18 months, 12 were null whilst the anxious/depressed subscale was slightly
worse in the DHA groups, even though the Bayley-III measures at the same time point were
null [113]. When these same children were followed up at 6 years and 3 subscales were
compared between groups, 2 showed no effect of DHA and the externalizing behavior scale
was worse in the DHA group which appeared to be driven by the oppositional defiance
sub-scale [114]. No differences were found in internalizing behavior or Total behavior at
6 years [114]. Nor were differences detected on the AQ-Child in this same trial at 6 years of
age [114].
(e) Self-reported behavior measures
None of the trials in infants asked children to rate their own behavioral functioning.
(f) Sensitivity and/or subgroup analyses
Of the seven trials conducted during infancy, there was only one that reported con-
ducting a subgroup analysis, for a sex by treatment interaction [114]. A sex by treatment
interaction was detected in which DHA group boys had higher externalizing behavior and
oppositional defiance than boys in the control group [114].
4. Discussion
This review is the first to focus on the effect of DHA supplementation in the first
1000 days on child behavioral functioning. At the time of this review, no study included be-
havioral functioning as a primary outcome or a main outcome of interest. Recent Cochrane
reviews of DHA interventions in the first 1000 days identified a total of 126 DHA RCTs
(70 in pregnancy [69], 17 in preterm infants [70], 8 to breastfeeding women [71], and 31
in infants and toddlers [72]). However, only 25 of these were eligible for inclusion in the
current review due to the absence of child behavior as an outcome in the vast majority (80%)
of intervention trials. Behavior, when measured, was generally a secondary or exploratory
outcome, and findings are subject to type 1 errors.
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There were no effects of a DHA intervention detected on behavior problems, or overall
behavioral scores or subscale scores for 19 included RCTs [80–85,89–97,103–106,109–112,115].
Contrary to expectations, only one study identified a potential beneficial effect of DHA
supplementation, on 3 out of 55 behavioral group comparisons [101,102]. There were
six studies (one prenatal RCT [86–88], two preterm neonate trials (including the one that
found a potential benefit) [98–101], one in breastfeeding women [107], and two directly in
infants [108,113,114]) in which one or more comparisons (total 23) indicated an adverse
effect of DHA intervention on a behavioral outcome. Importantly, in all of these studies,
there were multiple behavioral outcomes and the majority of behavioral comparisons were
null [86–88,98–101,107,108,113,114]. Of the larger 2 trials, there was 6 instances of a worse
score in the DHA group out of 43 comparisons in one [86–88], and 8 instances of a worse
score from 59 comparisons in the other [99,100]. Most differences in the latter trial were
within girls only [99,100], whilst two other studies found that it was boys who had poorer
scores after supplementation with DHA [107,113,114]. Few studies reported diagnosed
behavioral problems, and those that did found no group differences. All reported differ-
ences were in parent-rated measures, although admittedly the majority of measures were
parent-rated. However, given the prevalence of diagnoses for behavioral problems and the
sample sizes of included studies, a difference in the proportion of diagnosed problems is
unlikely to be detected as most studies were underpowered.
Between the 25 RCTs included in our review, there were 71 assessments of behavior
administered, and 401 group comparisons of a behavioral outcome, meaning that for
each behavioral assessment, there was an average of 5 comparisons. The heterogeneity
of the behavioral assessments, study characteristics and group comparisons conducted
prevented combining the data in a meta-analysis. Measures of behavior typically involve
an overall score made up of several subscale scores that reflect specific, individual aspects
of behavior, such as hyperactivity or impulsiveness. Exploration of individual domains of
behavior is important for discerning whether DHA effects behavior globally or particular
aspects of behavior only, although this does further increase the risk of a type 1 error.
Furthermore, of the 10,032 participants enrolled in these trials, behavioral outcomes were
reported for only 6867 children, equating to an overall average drop-out rate of almost
35%, meaning that attrition bias is likely [118]. The largest losses to follow-up were from
the trials with a maternal intervention during pregnancy (58%) possibly due to post-
randomization exclusion of infants born preterm by some trials, whilst trials conducted
in preterm infants had the highest retention (84%). Furthermore, there was evidence of
publication bias, where results of one follow-up were available only as an abstract from
conference proceedings [91], and results of another study were available as a doctoral
dissertation [81].
Of the two potentially eligible trials that were excluded, one found no effect of the egg
intervention on Personal–Social behavior [116] and the other reported improvements in
some but not all behavioral scores after supplementation for 31 preterm-born children who
displayed symptoms of ASD [117]. Including these studies in the review would not have
impacted our conclusion.
DHA is widely thought to be beneficial for brain development. There is currently no
clear mechanism for DHA supplementation to cause harm, although it may be that excess
DHA is detrimental. A recent RCT found that providing high-dose DHA to pregnant
women with low omega-3 long-chain polyunsaturated fatty acid status was beneficial
for protecting against early preterm birth (<34 weeks’ gestation), but in women with
higher omega-3 long-chain polyunsaturated fatty acid status, high-dose DHA interven-
tion appeared to increase the risk of early preterm birth [119]. Among the very and
extremely preterm infant population (<29 weeks’ gestation at birth), new evidence is
emerging that high-dose DHA supplementation may increase the risk of the serious lung
condition, bronchopulmonary dysplasia [120,121]. In animal models, suggested adverse
effects of DHA have included a shortened lifespan in mice on a long-term fish oil diet,
apparently due to oxidative stress and decreased cellular function [122] as well as detrimen-
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tal proliferation of neural stem progenitor cells in rats fed high-dose DHA [123]. However,
the potential of these suggested mechanisms to account for adverse effects of DHA sup-
plementation detected in human studies needs to be established. It is also possible that
behavioral development is particularly sensitive to exposure to nutrients in excess of needs
during fetal development, as has been seen with other nutrients such as iron exposure in
pregnancy [124].
Our review of the effect of a DHA intervention in the first 1000 days on behav-
ioral development has a similar conclusion to reviews of DHA supplementation over the
same period on cognition, motor or visual development [76], or language abilities [78].
Additionally, several reviews and meta-analyses of more specific windows within the
first 1000 days have identified little, if any evidence of benefits of DHA supplementation
for brain development [68–72,74,125]. Our previous review of DHA interventions and
subsequent language abilities revealed that whilst the majority of language measures were
null, four suggested a benefit and two suggested an adverse effect [78]. Differences in
findings between RCTs of DHA supplementation and observational studies of dietary
sources of DHA could be due to a number of reasons, such as additional nutrients present
in foods naturally rich in DHA and the inherent confounding in observational studies
due to the difficulty in adjusting for complex confounding factors [67]. For example,
several factors found to be associated with low fish consumption such as being a single
parent, lower levels of maternal education, high level of family adversity, crowding in
the family home and not being a homeowner as well as poor lifestyle factors such as not
breastfeeding, low parenting scores and smoking [16] are also considered to influence child
developmental outcomes. Furthermore, there is evidence to suggest that cohort studies
have a tendency to inflate positive effects compared with RCTs. One notable study found
56% of non-randomised trials found a positive treatment effect compared with 30% of
RCT [126] and this finding has been replicated in other studies [126–129].
We have determined that the existing evidence does not conclusively support or refute
the hypothesis that DHA supplementation in the first 1000 days of life improves children’s
behavioral functioning, but that it may in fact adversely affect behavior. Our interpretation
should be considered in light of the limitations of the body of literature, and any potentially
negative effect would need to be verified in future research. Whilst it would be unethical
to commence a new intervention with DHA in the first 1000 days specifically to determine
adversity, we strongly recommend that behavioral assessments be added as outcomes to
new trials, and to follow-up studies for existing trials. Many behavioral assessments are
quick and easy to administer with versions for parent and teachers to complete, as well
as self-report for literate children. The SDQ for example is a readily available behavioral
screening tool that takes approximately 5 min to complete.
5. Conclusions
Although there is a plethora of DHA interventions in the first 1000 days, only a
small proportion (less than one-quarter) appear to include a measure of child behavior.
This review is the first attempt to synthesize the results of these behavioral outcomes.
Of the 71 behavioral measures, there were 401 comparisons reported in the included
studies, and the vast majority detected a null effect. There were 6 trials with 23 parent-rated
outcomes that highlighted a potentially adverse effect of DHA on behavior, and one of
these trials also detected a potential benefit of DHA on behavior. No differences were
reported in the prevalence of clinically diagnosed behavioral problems such as ASD or
ADHD. However, at present, the evidence is insufficient to reach a definitive conclusion
regarding the effect of early DHA interventions on child behavior. Given the paucity of
evidence, we do not recommend that pregnant women, infants or young children consume
DHA supplements in order to improve behavioral functioning. This review highlights
the need for future RCTs, as well as future follow-ups of existing RCTs to prioritize child
behavior as an outcome.
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